Association study of the complement component C4 gene and suicide risk in schizophrenia.


Journal

Schizophrenia (Heidelberg, Germany)
ISSN: 2754-6993
Titre abrégé: Schizophrenia (Heidelb)
Pays: Germany
ID NLM: 9918367987006676

Informations de publication

Date de publication:
10 Feb 2024
Historique:
received: 19 09 2023
accepted: 23 01 2024
medline: 11 2 2024
pubmed: 11 2 2024
entrez: 10 2 2024
Statut: epublish

Résumé

Schizophrenia is a severe mental illness and a major risk factor for suicide, with approximately 50% of schizophrenia patients attempting and 10% dying from suicide. Although genetic components play a significant role in schizophrenia risk, the underlying genetic risk factors for suicide are poorly understood. The complement component C4 gene, an immune gene involved in the innate immune system and located in the major histocompatibility complex (MHC) region, has been identified to be strongly associated with schizophrenia risk. In addition, recent findings have also suggested that the MHC region has been associated with suicide risk across disorders, making C4 a potential candidate of interest for studying suicidality in schizophrenia patients. Despite growing interest in investigating the association between the C4 gene and schizophrenia, to our knowledge, no work has been done to examine the potential of C4 variants as suicide risk factors in patients with schizophrenia. In this study, we investigated the association between different C4 copy number variants and predicted C4 brain expression with suicidal outcomes (suicide attempts/suicidal ideation). We directly genotyped 434 schizophrenia patients to determine their C4A and C4B copy number variants. We found the C4AS copy number to be marginally and negatively associated with suicide risk, potentially being protective against suicide attempts (OR = 0.49; p = 0.05) and suicidal ideation (OR = 0.65; p = 0.07). Furthermore, sex-stratified analyses revealed that there are no significant differences between males and females. Our preliminary findings encourage additional studies of C4 and potential immune dysregulation in suicide.

Identifiants

pubmed: 38341430
doi: 10.1038/s41537-024-00440-w
pii: 10.1038/s41537-024-00440-w
doi:

Types de publication

Journal Article

Langues

eng

Pagination

14

Informations de copyright

© 2024. The Author(s).

Références

Meltzer, H. Y. Clozapine treatment for suicidality in schizophrenia international suicide prevention trial (InterSePT). Arch. Gen. Psychiatry 60, 82 (2003).
doi: 10.1001/archpsyc.60.1.82 pubmed: 12511175
Zaheer, J. et al. Predictors of suicide at time of diagnosis in schizophrenia spectrum disorder: A 20-year total population study in Ontario, Canada. Schizophr. Res. 222, 382–388 (2020).
doi: 10.1016/j.schres.2020.04.025 pubmed: 32507375
Voracek, M. & Mariella Loibl, L. Genetics of Suicide: A systematic review of twin studies. Wiener Klinische Wochenschrift 119, 463–475 (2007).
doi: 10.1007/s00508-007-0823-2 pubmed: 17721766
Strawbridge, R. et al. Identification of novel genome-wide associations for suicidality in UK biobank, genetic correlation with psychiatric disorders and polygenic association with completed suicide. EBioMedicine 41, 517–525 (2019).
doi: 10.1016/j.ebiom.2019.02.005 pubmed: 30745170 pmcid: 6442001
Ruderfer, D. M. et al. Significant shared heritability underlies suicide attempt and clinically predicted probability of attempting suicide. Mol. Psychiatry 25, 2422–2430 (2020).
doi: 10.1038/s41380-018-0326-8 pubmed: 30610202
Mullins, N. et al. Dissecting the shared genetic architecture of suicide attempt, psychiatric disorders, and known risk factors. Biol. Psychiatry 9, 313–327 (2022).
doi: 10.1016/j.biopsych.2021.05.029
Kimbrel, N. A. et al. A genome-wide association study of suicide attempts in the Million Veterans Program identifies evidence of pan-ancestry and ancestry-specific risk loci. Mol. Psychiatry 27, 2264–2272 (2022).
doi: 10.1038/s41380-022-01472-3 pubmed: 35347246 pmcid: 9910180
Docherty, A. R. et al. GWAS meta-analysis of suicide attempt: Identification of 12 genome-wide significant loci and implication of genetic risks for specific health factors. Am. J. Psychiatry 180, 723–738 (2023).
doi: 10.1176/appi.ajp.21121266 pubmed: 37777856 pmcid: 10603363
The International Schizophrenia Consortium Common Polygenic Variation Contributes to Risk of Schizophrenia and Bipolar Disorder. Nature 460, 748–752 (2009).
doi: 10.1038/nature08185
Shi, J. et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460, 753–757 (2009).
doi: 10.1038/nature08192 pubmed: 19571809 pmcid: 2775422
Schizophrenia Working Group of the Psychiatric Genomics Consortium: Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421–427 (2014).
Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature 604, 502–508 (2022).
doi: 10.1038/s41586-022-04434-5 pubmed: 35396580 pmcid: 9392466
McGuffin, P. & Power, R. A. Schizophrenia as a human leukocyte antigen-associated disease revisited. Am. J. Psychiatry 170, 821–823 (2013).
doi: 10.1176/appi.ajp.2013.13030336 pubmed: 23903329
Sekar, A. et al. Schizophrenia risk from complex variation of complement component 4. Nature 530, 177–183 (2016).
doi: 10.1038/nature16549 pubmed: 26814963 pmcid: 4752392
Jaimes-Bernal, C. P., Trujillo, M., José, F. M. & Caruz, A. Complement C4 gene copy number variation genotyping by high resolution melting PCR. Int. J. Mol. Sci. 21, 6309 (2020).
doi: 10.3390/ijms21176309 pubmed: 32878183 pmcid: 7504122
Law, K. S., Dodds, A. W. & Porter, R. R. A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J. 3, 1819–1823 (1984).
doi: 10.1002/j.1460-2075.1984.tb02052.x pubmed: 6332733 pmcid: 557602
Chung, K. et al. Genetic sophistication of human complement components C4A and C4B and RP-C4-CYP21-TNX (RCCX) modules in the major histocompatibility complex. Am. J. Hum. Genet. 71, 823–837 (2002).
doi: 10.1086/342777 pubmed: 12226794 pmcid: 378539
Mack, M., Bender, K. & Schneider, P. M. Detection of retroviral antisense transcripts and promoter activity of the HERV-K(C4) insertion in the MHC Class III region. Immunogenetics. 56, https://doi.org/10.1007/s00251-004-0705-y (2004).
Woo, J. J., Pouget, J. G., Zai, C. C. & Kennedy, J. L. The complement system in schizophrenia: where are we now and what’s next? Mol. Psychiatry 25, 114–130 (2020).
doi: 10.1038/s41380-019-0479-0 pubmed: 31439935
Hatzimanolis, A. et al. Deregulation of complement components C4A and CSMD1 peripheral expression in first-episode psychosis and links to cognitive ability. Eur. Arch. Psychiatry Clin. Neurosci. 272, 1219–1228 (2022).
doi: 10.1007/s00406-022-01409-5 pubmed: 35532796 pmcid: 9508018
Rey, R. et al. Overexpression of complement component C4 in the dorsolateral prefrontal cortex, parietal cortex, superior temporal gyrus and associative striatum of patients with schizophrenia. Brain, Behav., Immunity 90, 216–225 (2020).
doi: 10.1016/j.bbi.2020.08.019
Purves-Tyson, T. D. et al. Increased macrophages and C1qA, C3, C4 transcripts in the midbrain of people with schizophrenia. Front. Immunol. 11, 2002 (2020).
doi: 10.3389/fimmu.2020.02002 pubmed: 33133060 pmcid: 7550636
Howes, O. D. & Onwordi, E. C. The synaptic hypothesis of schizophrenia version III: A master mechanism. Mol. Psychiatry. https://doi.org/10.1038/s41380-023-02043-w (2023).
Mayilyan, K. R., Weinberger, D. R. & Sim, R. B. The complement system in schizophrenia. Drug News Persp. 21, 200–210 (2008).
doi: 10.1358/dnp.2008.21.4.1213349
Rudduck, C., Beckman, L., Franzen, G., Jacobsson, L. & Lindstrom, L. Complement factor C4 in schizophrenia. Hum. Heredity 35, 223–226 (1985).
doi: 10.1159/000153549 pubmed: 3875548
Druart, M. et al. Elevated expression of complement C4 in the mouse prefrontal cortex causes schizophrenia-associated phenotypes. Molecular Psychiatry 26, 3489–3501 (2021).
doi: 10.1038/s41380-021-01081-6 pubmed: 33837272
Zhang, R. et al. Dorsolateral and ventrolateral prefrontal cortex structural changes relative to suicidal ideation in patients with depression. Acta Neuropsychiatrica 32, 84–91 (2020).
doi: 10.1017/neu.2019.45 pubmed: 31753044
Alacreu-Crespo, A. et al. Prefrontal activation in suicide attempters during decision making with emotional feedback. Transl. Psychiatry 10, 313 (2020).
doi: 10.1038/s41398-020-00995-z pubmed: 32948747 pmcid: 7501865
Yilmaz, M. et al. Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice. Nat. Neurosci. 24, 214–224 (2021).
doi: 10.1038/s41593-020-00763-8 pubmed: 33353966
Onwordi, E. C. et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat. Commun. 11, 246 (2020).
doi: 10.1038/s41467-019-14122-0 pubmed: 31937764 pmcid: 6959348
Lewis, C. P. et al. Altered anterior cingulate glutamatergic metabolism in depressed adolescents with current suicidal ideation. Transl. Psychiatry 10, 119 (2020).
doi: 10.1038/s41398-020-0792-z pubmed: 32327639 pmcid: 7181616
Illarionova, A. E., Vinogradova, T. V. & Sverdlov, E. D. Only those genes of the KIAA1245 gene subfamily that contain HERV(K) LTRs in their introns are transcriptionally active. Virology 358, 39–47 (2007).
doi: 10.1016/j.virol.2006.06.027 pubmed: 16997346
Montesion, M., Bhardwaj, N., Williams, Z. H., Kuperwasser, C. & Coffin, J. M. Mechanisms of HERV-K (HML-2) transcription during human mammary epithelial cell transformation. J. Virol. 92, e01258–17 (2018).
doi: 10.1128/JVI.01258-17 pubmed: 29046454
Kamitaki, N. et al. Complement genes contribute sex-biased vulnerability in diverse disorders. Nature 582, 577–581 (2020).
doi: 10.1038/s41586-020-2277-x pubmed: 32499649 pmcid: 7319891
American Psychiatric Association, D. S. M. T. F. & American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5 (Vol. 5, No. 5). Washington, DC: American psychiatric association. (2013).
Beck, A. T., Steer, R. A. & Ranieri, W. F. Scale for suicide ideation: psychometric properties of a self-report version. J. Psychol. 44, 499–505 (1988).
Lahiri, D. K. & Nurnberger, J. I. Jr A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 19, 5444 (1991).
doi: 10.1093/nar/19.19.5444 pubmed: 1681511 pmcid: 328920
Zai, C. C. et al. Association study of the complement component C4 gene in tardive dyskinesia. Front. Pharmacol. 10, 1339 (2019).
doi: 10.3389/fphar.2019.01339 pubmed: 31849639 pmcid: 6901959

Auteurs

Mahbod Ebrahimi (M)

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.
Institute of Medical Science, University of Toronto, Toronto, Canada.

Kowsar Teymouri (K)

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.
Institute of Medical Science, University of Toronto, Toronto, Canada.

Cheng C Chen (CC)

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.
Institute of Medical Science, University of Toronto, Toronto, Canada.

Ayeshah G Mohiuddin (AG)

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.

Jennie G Pouget (JG)

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.

Vanessa F Goncalves (VF)

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.
Institute of Medical Science, University of Toronto, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.

Arun K Tiwari (AK)

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.

Clement C Zai (CC)

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.
Institute of Medical Science, University of Toronto, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.

James L Kennedy (JL)

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada. jim.kennedy@camh.ca.
Institute of Medical Science, University of Toronto, Toronto, Canada. jim.kennedy@camh.ca.
Department of Psychiatry, University of Toronto, Toronto, Canada. jim.kennedy@camh.ca.

Classifications MeSH